long intergenic non-protein coding RNA 2819Genealiases: []
Q-omics provides the consensus-scored LINC02819 profile across patient tissues and cancer cell-line models. LINC02819 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LINC02819 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, LINC02819 RNA expression shows 6,356 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, LIHC, and STAD as cancer lineages where LINC02819 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02819 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02819 survival associations across molecular data types. LINC02819 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02819 RNA expression–survival associations across cancer types. High LINC02819 expression shows unfavorable associations in CHOL, ACC, STAD, BRCA, GBM and BLCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for LINC02819 RNA expression.
This table summarizes LINC02819 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02819. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02819 shows lower tumor expression in CHOL and higher tumor expression in LIHC. The LIHC box plot shows higher LINC02819 RNA expression in tumor versus normal tissue (log2 FC = +0.745, t-test p < 0.001).
This table shows molecular features associated with LINC02819 in patient tissues and cancer cell lines. In patient samples, LINC02819 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
